BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15719368)

  • 1. CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes.
    Facchinetti V; Seresini S; Longhi R; Garavaglia C; Casorati G; Protti MP
    Eur J Immunol; 2005 Mar; 35(3):806-15. PubMed ID: 15719368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
    de Jong A; van der Burg SH; Kwappenberg KM; van der Hulst JM; Franken KL; Geluk A; van Meijgaarden KE; Drijfhout JW; Kenter G; Vermeij P; Melief CJ; Offringa R
    Cancer Res; 2002 Jan; 62(2):472-9. PubMed ID: 11809698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.
    van den Hende M; Redeker A; Kwappenberg KM; Franken KL; Drijfhout JW; Oostendorp J; Valentijn AR; Fathers LM; Welters MJ; Melief CJ; Kenter GG; van der Burg SH; Offringa R
    J Infect Dis; 2010 Oct; 202(8):1200-11. PubMed ID: 20822453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
    Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
    Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
    Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein.
    Bartholomew JS; Stacey SN; Coles B; Burt DJ; Arrand JR; Stern PL
    Eur J Immunol; 1994 Dec; 24(12):3175-9. PubMed ID: 7805746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of seroreactive epitopes of human papillomavirus type 18 E7 protein by synthetic peptides.
    Krchnák V; Pistĕk T; Vágner J; Suchánková A; Kañka J; Ritterová L; Vonka V
    Acta Virol; 1993 Oct; 37(5):395-402. PubMed ID: 7514354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
    Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
    Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7.
    Rudolf MP; Man S; Melief CJ; Sette A; Kast WM
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):788s-795s. PubMed ID: 11300474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of B-epitopes in the human papillomavirus 18 E7 open reading frame protein.
    Selvey LA; Tindle RW; Geysen HM; Haller CJ; Smith JA; Frazer IH
    J Immunol; 1990 Nov; 145(9):3105-10. PubMed ID: 1698872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
    Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
    Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.